{"id":71541,"date":"2026-08-03T14:30:54","date_gmt":"2026-08-03T06:30:54","guid":{"rendered":"https:\/\/flcube.com\/?p=71541"},"modified":"2026-08-03T14:30:55","modified_gmt":"2026-08-03T06:30:55","slug":"insilico-medicines-nlrp3-inhibitor-ism8969-secures-nmpa-ind-approval-for-parkinsons-disease-with-global-clinical-trials-underway","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71541","title":{"rendered":"Insilico Medicine&#8217;s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson&#8217;s Disease with Global Clinical Trials Underway"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3696:HKG\">HKG: 3696<\/a>) announced that <strong>ISM8969\/HT-001<\/strong>, an innovative oral <strong>NLRP3 inflammasome inhibitor<\/strong> co-developed with <strong>Hygtia Therapeutics<\/strong>, has received <strong>Investigational New Drug (IND) approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>Parkinson&#8217;s disease<\/strong>, marking a significant milestone in the development of novel neuroinflammatory therapeutics targeting central nervous system disorders.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Compound<\/strong><\/td><td>ISM8969\/HT-001 (oral NLRP3 inflammasome inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Parkinson&#8217;s disease<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Investigational New Drug (IND)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>03 Aug 2026<\/td><\/tr><tr><td><strong>Clinical Status<\/strong><\/td><td>Phase I trials initiated in China and Australia<\/td><\/tr><tr><td><strong>Key Property<\/strong><\/td><td>Blood-brain barrier permeability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-therapeutic-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Therapeutic Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Potentially best-in-class oral small-molecule <strong>NLRP3 inflammasome inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Target Pathway:<\/strong> NLRP3 inflammasome\u2014a key driver of chronic neuroinflammation in neurodegenerative diseases<\/li>\n\n\n\n<li><strong>Delivery Advantage:<\/strong> Oral administration with demonstrated <strong>blood-brain barrier permeability<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Scope:<\/strong> Designed for chronic neuroinflammation and broader CNS disorders beyond Parkinson&#8217;s disease<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> First-in-human clinical evaluation following successful preclinical studies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-framework\" class=\"wp-block-heading\">Strategic Partnership Framework<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Insilico Medicine has established an <strong>exclusive global strategic partnership<\/strong> with Hygtia Therapeutics, structured as follows:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rights Granted:<\/strong> Hygtia receives global rights to research, develop, register, manufacture, and commercialize ISM8969<\/li>\n\n\n\n<li><strong>Ownership Structure:<\/strong> Equal 50\/50 global stake sharing between both parties<\/li>\n\n\n\n<li><strong>Geographic Scope:<\/strong> Worldwide development and commercialization rights<\/li>\n\n\n\n<li><strong>Strategic Rationale:<\/strong> Leverages Insilico&#8217;s AI-driven drug discovery capabilities with Hygtia&#8217;s clinical development expertise<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Parkinson&#8217;s Disease Market:<\/strong> Global market valued at approximately $5.8 billion in 2025, projected to reach $8.2 billion by 2030, driven by aging demographics and unmet therapeutic needs<\/li>\n\n\n\n<li><strong>Neuroinflammation Targeting:<\/strong> NLRP3 represents an emerging target class with limited clinical validation, offering first-mover advantage potential<\/li>\n\n\n\n<li><strong>Blood-Brain Barrier Challenge:<\/strong> Oral compounds with proven BBB permeability represent a significant competitive differentiator in CNS drug development<\/li>\n\n\n\n<li><strong>AI-Driven Discovery:<\/strong> ISM8969 exemplifies the growing trend of AI-accelerated drug discovery translating into clinical candidates with novel mechanisms<\/li>\n\n\n\n<li><strong>Global Development Strategy:<\/strong> Simultaneous trials in China and Australia reflect efficient regulatory pathway optimization and risk diversification<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-investment-implications-amp-forward-outlook\" class=\"wp-block-heading\">Investment Implications &amp; Forward Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The IND approval validates Insilico Medicine&#8217;s AI-powered drug discovery platform and positions the company at the forefront of neuroinflammation-targeted therapeutics. The 50\/50 partnership structure ensures meaningful economic participation while sharing development costs and risks.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts note that successful clinical development could establish ISM8969 as a cornerstone therapy for Parkinson&#8217;s disease and potentially expand into other neurodegenerative conditions including Alzheimer&#8217;s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The dual-country clinical trial initiation demonstrates sophisticated regulatory strategy execution, potentially accelerating time-to-market through parallel development pathways while maintaining optionality for regional commercial partnerships.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for ISM8969. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080300064_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080300064_c.\"><\/object><a id=\"wp-block-file--media-11345fc3-caba-4fbb-aa1d-c4b91bab0f97\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080300064_c.pdf\">2026080300064_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080300064_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-11345fc3-caba-4fbb-aa1d-c4b91bab0f97\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced that ISM8969\/HT-001, an innovative oral NLRP3 inflammasome inhibitor co-developed with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,4514,164],"class_list":["post-71541","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine&#039;s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson&#039;s Disease with Global Clinical Trials Underway - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced that ISM8969\/HT-001, an innovative oral NLRP3 inflammasome inhibitor co-developed with Hygtia Therapeutics, has received Investigational New Drug (IND) approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of Parkinson&#039;s disease, marking a significant milestone in the development of novel neuroinflammatory therapeutics targeting central nervous system disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71541\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine&#039;s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson&#039;s Disease with Global Clinical Trials Underway\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced that ISM8969\/HT-001, an innovative oral NLRP3 inflammasome inhibitor co-developed with Hygtia Therapeutics, has received Investigational New Drug (IND) approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of Parkinson&#039;s disease, marking a significant milestone in the development of novel neuroinflammatory therapeutics targeting central nervous system disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71541\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T06:30:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T06:30:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71541#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71541\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine&#8217;s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson&#8217;s Disease with Global Clinical Trials Underway\",\"datePublished\":\"2026-08-03T06:30:54+00:00\",\"dateModified\":\"2026-08-03T06:30:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71541\"},\"wordCount\":479,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71541#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71541\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71541\",\"name\":\"Insilico Medicine's NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson's Disease with Global Clinical Trials Underway - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-03T06:30:54+00:00\",\"dateModified\":\"2026-08-03T06:30:55+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced that ISM8969\\\/HT-001, an innovative oral NLRP3 inflammasome inhibitor co-developed with Hygtia Therapeutics, has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for the treatment of Parkinson's disease, marking a significant milestone in the development of novel neuroinflammatory therapeutics targeting central nervous system disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71541#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71541\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71541#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine&#8217;s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson&#8217;s Disease with Global Clinical Trials Underway\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine's NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson's Disease with Global Clinical Trials Underway - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced that ISM8969\/HT-001, an innovative oral NLRP3 inflammasome inhibitor co-developed with Hygtia Therapeutics, has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for the treatment of Parkinson's disease, marking a significant milestone in the development of novel neuroinflammatory therapeutics targeting central nervous system disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71541","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine's NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson's Disease with Global Clinical Trials Underway","og_description":"Insilico Medicine (HKG: 3696) announced that ISM8969\/HT-001, an innovative oral NLRP3 inflammasome inhibitor co-developed with Hygtia Therapeutics, has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for the treatment of Parkinson's disease, marking a significant milestone in the development of novel neuroinflammatory therapeutics targeting central nervous system disorders.","og_url":"https:\/\/flcube.com\/?p=71541","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-03T06:30:54+00:00","article_modified_time":"2026-08-03T06:30:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71541#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71541"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine&#8217;s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson&#8217;s Disease with Global Clinical Trials Underway","datePublished":"2026-08-03T06:30:54+00:00","dateModified":"2026-08-03T06:30:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71541"},"wordCount":479,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 3696","Insilico Medicine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71541#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71541","url":"https:\/\/flcube.com\/?p=71541","name":"Insilico Medicine's NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson's Disease with Global Clinical Trials Underway - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-03T06:30:54+00:00","dateModified":"2026-08-03T06:30:55+00:00","description":"Insilico Medicine (HKG: 3696) announced that ISM8969\/HT-001, an innovative oral NLRP3 inflammasome inhibitor co-developed with Hygtia Therapeutics, has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for the treatment of Parkinson's disease, marking a significant milestone in the development of novel neuroinflammatory therapeutics targeting central nervous system disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71541#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71541"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71541#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine&#8217;s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson&#8217;s Disease with Global Clinical Trials Underway"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71541"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71541\/revisions"}],"predecessor-version":[{"id":71543,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71541\/revisions\/71543"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}